Healthcare, Financials Jan 04, 2022 12:28 PM (GMT+8)
Cailian news agency, Jan. 4, learned from Jiuzhitang that the company has officially issued a price adjustment notice to customers on January 1. Considering the impact of the price increase of raw materials, it has raised the supply price or recommended retail price of 21 Chinese patent medicines, including Angong Niuhuang Pill, Liuwei Dihuang pill and Xiaoyao Pill, with a price adjustment range of 6% - 30%, Among them, the price of Angong Niuhuang Pill increased by 12% - 25%, and Liuwei Dihuang pill, which accounts for the largest proportion of OTC product revenue, increased by 10%. It is understood that these 21 drugs account for about 30% of the company's OTC drug business revenue by 2020.
This text is a result of machine translation.